HOME >> MEDICINE >> NEWS
Novartis MS drug shows promising results

ronic, disabling disease of the central nervous system affecting twice as many women than men.3 MS has a significant impact on the patient's social activities, employment and overall quality of life. Currently marketed MS therapies afford an average reduction in relapse rates of 30% in two-year studies and require frequent injections ranging from daily to weekly. , , ,

FTY720 Phase II study results
The results are from a large Phase II study conducted at 32 centers in 11 countries (Europe and Canada). In the initial, placebo-controlled part of this study, 281 patients were randomized in equal numbers to receive either placebo, 1.25 mg or 5.0 mg FTY720 orally once-daily for six months. The study evaluated the effect of FTY720 on disease activity as measured by MRI and clinical relapses as well as its tolerability and safety. After six months, patients in the placebo group were re-randomized to receive either FTY720 1.25 mg or 5 mg blinded for an additional six months, while patients already on FTY720 continued their originally-assigned treatment. A total of 98% of the 255 patients who completed the first six months volunteered to continue in the extension phase evaluating the longer-term effects of FTY720.

In the 12-month analysis, both patient groups on FTY720 (1.25 mg and 5 mg) who had experienced a reduction in their annualized relapse rate of more than 50% during the first six months compared to placebo maintained this low relapse rate during the subsequent six-month extension. In those patients who switched from placebo to either 1.25 mg or 5 mg of FTY720 after six months, the annualized relapse rate was reduced by at least 70% during the second six-month study phase compared to the first six months on placebo.

The MRI results at 12 months showed low levels of inflammatory disease activity in all FTY720 groups. In patients who switched from placebo to FTY720, the mean number of inflammatory (Gd-enhancing) lesions on M
'"/>

Contact: Eva Reynolds
eva@reynoldsmackenzie.com
44-207-031-4361
Reynolds-MacKenzie
1-Oct-2005


Page: 1 2 3

Related medicine news :

1. BIDMC investigator receives Novartis Award in Diabetes
2. American Urological Association honors Novartis Pharmaceuticals with annual health science award
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Most seniors now have drug coverage, U-M study shows
5. Wireless technology shows promise in diagnosing pediatric intestinal disease
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Method shows promise for early detection of pancreatic cancer
8. Organic farming can feed the world, U-M study shows
9. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
10. Borderline personality disorder shows improvements with intensive psychotherapy
11. New drug shows promise in treatment of advanced thyroid cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... ... August 21, 2019 , ... CBD has officially ... video accompanying this announcement is available at: https://youtu.be/D-65LmBhJhU , CBD, the ... can be found on the internet, wellness catalogs, small specialty shops, and now, ...
(Date:8/21/2019)... ... August 21, 2019 , ... Photoprotective Technologies (PPT) has ... This water-based ingredient is currently used in skincare products such as creams or makeup ... product addresses the growing need to protect the skin from blue light as well ...
(Date:8/19/2019)... , ... August 19, 2019 , ... ... selling Eminence Organic Skin Care products , the authorized retailer will change ... DeVries, was a practicing esthetician in Florida providing Eminence Organic Skin Care facials ...
(Date:8/19/2019)... ... August 19, 2019 , ... Cosmetic Town, an online ... the best hair restoration doctors in New York currently providing a lifetime of natural ... starting to see some thinning hair. Cosmetic Town makes the process of finding information ...
(Date:8/16/2019)... ... August 16, 2019 , ... Cannabinoid Biosciences (“CBDZ”), ... cannabidiol (CBD) products across the CBD market in the United States in particular ... to raise $50 million on September 9, 2019. , Established on May 6, ...
Breaking Medicine News(10 mins):
(Date:8/21/2019)... ... August 21, 2019 , ... ... ranked by Modern Healthcare’s Construction and Design Survey, has added Operational Readiness ... provides a comprehensive overlay to clients’ capital projects, working with the clinical ...
(Date:8/21/2019)... ... 2019 , ... Dr. Leonard Bley at NY LASIK is proud ... (Small Incision Lenticule Extraction) located in their state-of-the-art Manhattan surgery center. NY LASIK is ... area. SMILE is a one-step, one laser procedure that is more minimally invasive than ...
(Date:8/21/2019)... Colo. (PRWEB) , ... August 21, 2019 , ... ... improving patron experience by lowering pool chemical use with Clear Comfort’s Advanced Oxidation ... is able to save significant chemical expense dollars, simplify its water care protocol ...
Breaking Medicine Technology:
Cached News: